This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): AbGn-168H, AbGn 168
Description: AbGn-168 is an immunomodulating investigational therapeutic monoclonal antibody that specifically depletes chronic activated T cells for treatment of autoimmune diseases.
Deal Structure: In May 2005, Boehringer Ingelheim and AbGenomics announced that AbGn-168 is exclusively licensed to Boehringer Ingelheim. Boehringer Ingelheim is solelyresponsible for further development and commercialization of AbGn-168 and AbGenomics iseligible to receive development milestone payments and royalties on any sales of AbGn-168.
In December 2011, AbGenomics announced that, effective February 13, 2012, it will regain global rights to AbGn-168H as part of an agreedupon arrangement following the termination of its collaboration with Boehringer Ingelheim.
Additional information available to subscribers only: